The Initiative will build on and coordinate multiple efforts within the company, including corporate venture capital, open innovation, R&D, and health care lines of business. This includes previously announced efforts at GE, such as the work that the company has done to convene the traumatic brain injury community and support for “Brain Trust” meetings of thought leaders.
OnAir Post: GE Brain Health Initiative
Principal Investigator: Baldwin Goodell
Gray Matter Research focuses on Microdrive Systems and Recording Chamber Systems. For the BRAIN Initiative, Goodell and his colleagues aim to develop optrodes, which are implantable columns of lights and wires for simultaneous electrical recording of neurons and delivery of light flashes to multiple brain areas.
Website: graymatter-research.com/ Brain Initiative Grant – “Large-Scale Electrophysiological Recording and Optogenetic Control System”
Email: baldwin@graymatter-research.com Phone: (406) 672-1915 Address: Gray Matter Research 920 Technology Blvd. Suite 106 Bozeman, MT 59718
OnAir Post: Gray Matter Research
Our vision for bioelectronic medicines is one of miniature, implantable devices that can be attached to individual peripheral nerves anywhere in the viscera.
Such devices would be able to decipher and modulate neural signalling patterns, bringing about therapeutic effects targeted at single functions of specific organs. GSK operates an exploratory research funding program; we have established a $50 million venture arm dedicated to technology and early bioelectronic treatment manifestations and an innovation challenge focussed on rapidly bringing visceral nerve research platforms to the community.
Website: http://www.gsk.com/en-gb/partnerships/bioelectronics-randd/
Email: roy.m.katso@gsk.com
GlaxoSmithKline is announcing up to $5 million in new funding for the research community to develop innovative peripheral neurotechnologies:
In 2013, GlaxoSmithKline (GSK) announced its ambition to develop new treatments for disease through neuronal control of visceral organs systems, an area where GSK believes there is opportunity for translation of innovative neurotechnology to create precision treatments for chronic diseases such as asthma, hypertension, and arthritis. Since then, the GSK Bioelectronic Medicines program has furthered work in the research community in this area through multiple efforts, including exploratory funding for academic scientists, a $50 million venture capital fund, and ...
OnAir Post: GSK Bioelectronics R&D
Leaders of the National Photonics Initiative (NPI), an alliance of top scientific societies uniting industry and academia to raise awareness of photonics, launched its Photonics Industry Neuroscience Group at the White House BRAIN Initiative launch conference.
Members of the NPI industry group are committing to invest upwards of $30 million in existing and future research and development spending over the next three years to advance optics and photonics technology in support of the White House BRAIN Initiative.
Website: lightourfuture.org/
Email: epappas@podestagroup.com (media contact) Phone: 231.357.6330
Director:
U.S. Photonics Industry Leaders are committing $30 million to tackle challenges of the BRAIN Initiative:
The National Photonics Initiative (NPI), an alliance of major scientific societies, industry and academic organizations, is convening a Photonics Industry Neuroscience Group to focus on developing new optics and photonics technologies in support of the BRAIN Initiative. This multidisciplinary industry group is comprised of influential U.S. industry leaders including Accumetra, LLC; Agilent, Applied Scientific Instrumentation; Coherent; Hamamatsu; Inscopix, Inc.; Spectra—Physics; and THORLABS. The Photonics Industry Neuroscience Group will work closely with the BRAIN Initiative leadership and with the neuroscience research community to advance optics and photonics research ...
OnAir Post: Photonics Industry Neuroscience Group
